Skip to main navigation
Skip to search
Skip to main content
University of Edinburgh Research Explorer Home
Help & FAQ
Home
Research output
Profiles
Research units
Projects
Datasets
Prizes
Activities
Press/Media
Equipment
Search by expertise, name or affiliation
Simvastatin in Critically Ill Patients with Covid-19
REMAP-CAP Investigators
Deanery of Clinical Sciences
Centre for Inflammation Research
Research output
:
Contribution to journal
›
Article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Simvastatin in Critically Ill Patients with Covid-19'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
COVID-19
100%
Simvastatin
100%
Patient
100%
Organ
37%
Odds Ratio
37%
Analysis
25%
Statin
25%
Survival
12%
Death
12%
Adverse Event
12%
Hazard Ratio
12%
Hospital
12%
Creatine Kinase
12%
Liver Enzyme
12%
Cardiovascular System
12%
Pharmacology, Toxicology and Pharmaceutical Science
Simvastatin
100%
Diseases
100%
Coronavirinae
100%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
12%
Creatine Kinase
12%
Adverse Event
12%
Death
12%
Liver Enzyme
12%
Survival
12%
Statin (Protein)
12%
Biochemistry, Genetics and Molecular Biology
Coronavirinae
100%
Simvastatin
100%
Statin
25%
Creatine Kinase
12%
Randomized Controlled Trial
12%
Lysozyme
12%
Survival
12%
Neuroscience
Coronavirus
100%
Simvastatin
100%
Randomized Controlled Trial
12%
Creatine Kinase
12%
Liver Enzyme
12%